BCPC on XNAS, Materials, Balchem Corporation, job postings
Measures activity, not value. Not investment advice.
Profit rose 15% to $170.9M over 12 months as quarterly revenue grew 8.6% to $290.7M.
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
expected around 19 Feb 2027 (an estimate: a year ago it reported on 20 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $290.7M, net income $46.7M.
31 Dec 2021RevenueNet incometallest bar $290.7M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$290.7M
$46.7M
30 Jun 2026
$284.0M
$44.6M
31 Mar 2026
$270.7M
$40.3M
31 Dec 2025
$263.6M
$39.2M
30 Sep 2025
$267.6M
$40.3M
30 Jun 2025
$255.5M
$38.3M
31 Mar 2025
$250.5M
$37.1M
31 Dec 2024
$240.0M
$33.6M
30 Sep 2024
$239.9M
$33.8M
30 Jun 2024
$234.1M
$32.1M
31 Mar 2024
$239.7M
$29.0M
31 Dec 2023
$228.7M
$26.6M
30 Sep 2023
$229.9M
$29.1M
30 Jun 2023
$231.3M
$30.1M
31 Mar 2023
$232.5M
$22.7M
31 Dec 2022
$232.5M
$21.4M
30 Sep 2022
$244.3M
$25.2M
30 Jun 2022
$236.7M
$29.8M
31 Mar 2022
$228.9M
$28.9M
31 Dec 2021
$213.1M
$24.9M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$1.1B
$1.0B
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+9.4%
-0.3%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$170.9M
$149.2M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$5.31
$4.57
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
36.5%
35.8%
22.0%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
20.7%
20.2%
-2.3%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
15.4%
14.7%
1.3%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
13.0%
1.7%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$66.3M
$65.1M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$124.0M
$154.0M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
$57.7M
$88.9M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.09
0.81
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$41.75
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
30.4
29.8
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
4.7
1.1
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
4.7
1.4
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
3.9
2.5
Dividend yieldiDividends per share declared in the latest fiscal year divided by the share price.
0.59%
2.0%
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
–
No data for this company
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+4.4%
427 13F filers vs 409
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
90%
28.4M shares held by 13F filers (30 Sep 2026) of 31.8M outstanding (15 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
1.6%
504K shares sold short (30 Oct 2026) of 31.8M outstanding (15 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
1.5
504K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-2.6%
517K shares sold short in the report before, 504K on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
52%
52% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 52%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+8.6%
$290.7M vs $267.6M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
4
4 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
4 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.
Price $163.54 on 20 Nov 2026, +7.1% over 12 months (12-month range $147.36 to $183.26)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders sold a net $2.2M in the last 12 months (the 12 months before: -$185K).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 3 published in the last 12 months, +200% on the 12 months before.Revenue per quarter. Revenue $290.7M in the latest quarter, +8.6% on a year earlier.Capital spending per quarter. Capital spending $8.3M in the latest quarter, -44% on a year earlier.Institutional holders (13F filers). 427 13F filers reported holding it in the latest 13F quarter, +11% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $213.1M, +18% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $228.9M, +23% on a year earlier; public on 30 Apr 2022
Quarter ended 30 Jun 2022: $236.7M, +17% on a year earlier; public on 30 Jul 2022
Quarter ended 30 Sep 2022: $244.3M, +23% on a year earlier; public on 5 Nov 2022
Quarter ended 31 Dec 2022: $232.5M, +9.1% on a year earlier; public on 25 Feb 2023
Quarter ended 31 Mar 2023: $232.5M, +1.6% on a year earlier; public on 29 Apr 2023
Quarter ended 30 Jun 2023: $231.3M, -2.3% on a year earlier; public on 29 Jul 2023
Quarter ended 30 Sep 2023: $229.9M, -5.9% on a year earlier; public on 28 Oct 2023
Quarter ended 31 Dec 2023: $228.7M, -1.6% on a year earlier; public on 17 Feb 2024
Quarter ended 31 Mar 2024: $239.7M, +3.1% on a year earlier; public on 4 May 2024
Quarter ended 30 Jun 2024: $234.1M, +1.2% on a year earlier; public on 27 Jul 2024
Quarter ended 30 Sep 2024: $239.9M, +4.3% on a year earlier; public on 26 Oct 2024
Quarter ended 31 Dec 2024: $240.0M, +4.9% on a year earlier; public on 22 Feb 2025
Quarter ended 31 Mar 2025: $250.5M, +4.5% on a year earlier; public on 25 Apr 2025
Quarter ended 30 Jun 2025: $255.5M, +9.1% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $267.6M, +12% on a year earlier; public on 22 Oct 2025
Quarter ended 31 Dec 2025: $263.6M, +9.8% on a year earlier; public on 21 Feb 2026
Quarter ended 31 Mar 2026: $270.7M, +8.1% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $284.0M, +11% on a year earlier; public on 1 Aug 2026
Quarter ended 30 Sep 2026: $290.7M, +8.6% on a year earlier; public on 24 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $14.6M, +14% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $9.7M, +63% on a year earlier; public on 30 Apr 2022
Quarter ended 30 Jun 2022: $10.4M, +45% on a year earlier; public on 30 Jul 2022
Quarter ended 30 Sep 2022: $14.8M, +76% on a year earlier; public on 5 Nov 2022
Quarter ended 31 Dec 2022: $14.1M, -3.0% on a year earlier; public on 25 Feb 2023
Quarter ended 31 Mar 2023: $9.6M, -1.0% on a year earlier; public on 29 Apr 2023
Quarter ended 30 Jun 2023: $7.9M, -24% on a year earlier; public on 29 Jul 2023
Quarter ended 30 Sep 2023: $8.3M, -44% on a year earlier; public on 28 Oct 2023
Institutional holders (13F filers)
31 Dec 2021 report: 257; public on 14 Feb 2022
31 Mar 2022 report: 277; public on 16 May 2022
30 Jun 2022 report: 261; public on 15 Aug 2022
30 Sep 2022 report: 254; public on 14 Nov 2022
31 Dec 2022 report: 266; public on 14 Feb 2023
31 Mar 2023 report: 263; public on 15 May 2023
30 Jun 2023 report: 259; public on 14 Aug 2023
30 Sep 2023 report: 269; public on 14 Nov 2023
31 Dec 2023 report: 276; public on 14 Feb 2024
31 Mar 2024 report: 304; public on 15 May 2024
30 Jun 2024 report: 315; public on 14 Aug 2024
30 Sep 2024 report: 339; public on 14 Nov 2024
31 Dec 2024 report: 350; public on 14 Feb 2025
31 Mar 2025 report: 360; public on 15 May 2025
30 Jun 2025 report: 381; public on 14 Aug 2025
30 Sep 2025 report: 385; public on 14 Nov 2025
31 Dec 2025 report: 393; public on 17 Feb 2026
31 Mar 2026 report: 412; public on 15 May 2026
30 Jun 2026 report: 409; public on 14 Aug 2026
30 Sep 2026 report: 427; public on 16 Nov 2026
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $2.2M (5 Dec 2025), 3.4× its normal reading; higher than 90% of its own history.
spent $12.8M on capital projects in the quarter ended 31 Dec 2020, 2.1× the same quarter last year.
Same quarter last year: $6.2M; its normal quarter is $6.2M.
See the evidence
This period
$12.8M (the quarter ended 31 Dec 2020)
Normal quarter (median of 8 earlier)
$6.2M
Typical spread (median absolute deviation)
$676K
How far from its usual level
+6.6
Same quarter last year
$6.2M
History used
3,745 days
the quarter ended 31 Dec 20208 earlier quartersnormal: $6.2M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
saw 27 13F filers open a new position in the quarter ended 31 Mar 2019, 1.7× the same quarter last year.
Same quarter last year: 16; its normal quarter is 16.
See the evidence
This period
27 (the quarter ended 31 Mar 2019)
Normal quarter (median of 8 earlier)
16
Typical spread (median absolute deviation)
2
How far from its usual level
+3.7
Same quarter last year
16
History used
2,008 days
the quarter ended 31 Mar 20198 earlier quartersnormal: 16
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Showing the newest 40 of 43 entries; narrow the window or the kind of data to see older ones.
Not listed: 138 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0000009326
Ticker
BCPC
Domain
balchem.com
Employer name
Balchem Corporation (1 unverified)
Hq location
NJ|MONTVALE|07645 (1 unverified)
Name
Aberco, Inc, Albion Laboratories, Inc, Balchem Canada Corporation, Balchem Corporation and 10 more
DOL H-1B labor condition applications and PERM certifications31 data points7 Dec 2020 to 11 May 2026
SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)124 records4 Feb 2016 to 23 Oct 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1175 data points31 Dec 2008 to 15 Oct 2026
SEC Form 4 insider transactions44 records, 160 data points23 Mar 2016 to 5 Dec 2025
FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026